Hanmi Pharm Co., Ltd.

Hanmi Signs Exclusive Partnership with New Mexican Partner Laboratorios Sanfer, Covering Efpeglenatide and Diabetes Treatments 

SEOUL, South Korea, Jan. 27, 2026 /PRNewswire/ -- Hanmi is accelerating its global market entry with efpeglenatide, Korea's first domestically developed GLP-1 class obesity and metabolic disease treatment.

Hanmi Pharmaceutical, the core operating company of Hanmi Science, announced on January 28 that it has signed an exclusive distribution agreement with Mexican pharmaceutical company Laboratorios Sanfer for efpeglenatide, its GLP-1 obesity therapy, as well as the Dapalon Family, Hanmi's flagship diabetes treatment portfolio (Dapalon Tab. and Dapalon Duo SR Tab.).

Under the agreement, Hanmi will supply efpeglenatide and the Dapalon Family, while Laboratorios Sanfer will be responsible for regulatory approval, marketing, distribution, and sales within Mexico.

Mexico is one of the countries with the highest obesity rates globally, with obesity prevalence reaching 36.86%, while diabetes prevalence stands at 16.4%.^[1] As demand in the market extends beyond weight loss and maintenance therapy to include blood glucose management, the agreement reflects confidence in efpeglenatide's global scalability and strategic value.

Founded in 1941, Sanfer is Mexico's largest privately held pharmaceutical company. Leveraging its extensive sales and distribution network across Latin America and its in-house R&D capabilities, Sanfer has established itself as a leading pharmaceutical company in the region. The company operates in more than 20 countries across Latin America as well as in the United States and recently strengthened its position as Mexico's largest biopharmaceutical company through the acquisition of Probiomed.

The partnership is expected to gradually expand collaboration across efpeglenatide and other metabolic disease treatments, including additional product launches and joint marketing strategies over the mid- to long term.

Ricardo Amtmann, CEO of Sanfer, stated, "As a leading pharmaceutical company in Mexico and Latin America, our vision is to improve patients' lives through innovative, high-quality products. With healthcare costs accounting for 34.6% of household spending in Mexico, improving accessibility to innovative treatments is critical.^[2] Hanmi's efpeglenatide and diabetes treatment portfolio meet these needs." He added, "Through this partnership, we aim to contribute to addressing the rapidly growing challenges of obesity and diabetes in Mexico."

Jae-hyun Park, CEO of Hanmi Pharmaceutical, said, "This agreement marks an important milestone that demonstrates Hanmi's formulation capabilities and R&D competitiveness on the global stage. As the Mexican government places greater emphasis on standardizing healthcare services and strengthening the management of chronic diseases, we find it especially meaningful that Hanmi's independently developed, Korea's first GLP-1–based obesity and metabolic disease treatment, together with our innovative diabetes treatment portfolio, will be able to contribute to improving the health of the Mexican population."

Meanwhile, Hanmi completed its regulatory application for efpeglenatide to the Ministry of Food and Drug Safety on December 17, 2025. In September 2025, the company also submitted an IND for a Phase 3 clinical trial evaluating combination therapy with SGLT-2 inhibitors and metformin, which was approved on January 21, 2026. Hanmi is pursuing an expansion of efpeglenatide's indications from obesity into diabetes, with obesity approval targeted for the second half of 2026 and an additional diabetes indication planned for 2028.

Contact info:

Official Websites: www.hanmipharm.com, www.linkedin.com/company/hanmipharm

innovation@hanmi.co.kr, +82-02-410-0467

View original content to download multimedia:https://www.prnewswire.com/news-releases/hanmi-secures-export-deal-with-mexican-partner-sanfer-for-glp-1-obesity-drug-and-more-302672036.html

SOURCE Hanmi Pharmaceutical

Hanmi Pharm Begins Local Sales of Urological Product 'Aditams' in Mexico with Partner 'Laboratorios Silanes' 

Launch completed in February, Hanmi Pharm's Third Product to Enter Latin America

Aditams, The First Urological Combination Drug for OPG and ED Exported to Mexico

SEOUL, South Korea, April 2, 2025 /PRNewswire/ -- Hanmi Pharmaceutical's combination therapy for Obstructive Prostatic Growth (OPG) caused by Benign Prostatic Hyperplasia (BPH) and Erectile Dysfunction (ED), Gugutams, is entering the Mexican market under the local brand name "Aditams."

Hanmi Pharmaceutical announced that it has completed the launch of Aditams in Mexico under the export agreement signed in October 2020 with the Mexican pharmaceutical company 'Laboratorios Silanes'. Under the agreement, Hanmi Pharmaceutical plans to export Gugutams to the Mexican market for a period of seven years, starting in February 2025.

Gugutams, developed by Hanmi Pharmaceutical, is the world's first urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). It is also noteworthy as the first prescription drug in Korea to apply Poly-Cap technology, which integrates multiple active ingredients into a single capsule.

Laboratorios Silanes, a leading pharmaceutical company in Mexico founded in 1943, is committed to providing innovative healthcare solutions and driving rapid growth in the industry. It has established itself as a key player in the Latin American pharmaceutical market through its robust distribution network and strategic collaborations with global partners.

Silanes previously collaborated with Hanmi Pharmaceutical in 2023 to successfully introduce the hypertension and dyslipidemia combination treatment 'Amosartan Q', under the local brand 'Lodarta' and in 2024 to introduce the combination hypertension treatment 'Amosartan Plus' under the local brand 'Bicartial-CTD'. Following these products, Gugutams, under the local brand 'Aditams', becomes Hanmi Pharmaceutical's third product in the Latin American region. 

Aditams, as the first urological combination therapy to enter the Mexican market, is expected to offer a new treatment option for patients suffering from both Obstructive Prostatic Growth (OPG) and erectile dysfunction (ED). By managing both conditions with a single medication, it significantly enhances patient convenience and maximizes therapeutic efficacy.

Hanmi continues to focus on expanding its partnerships in emerging markets such as the Middle East and Latin America, in addition to its established presence in developed markets like North America and Japan. The company aims to leverage strategic partners like Laboratorios Silanes as key footholds to broaden its product portfolio and regional reach.

Park Jae-hyun, CEO of Hanmi Pharmaceutical, stated, "As the first urological combination therapy to enter the Mexican market, Gugutams is expected to present a new treatment paradigm for local patients." He added, "Through this collaboration with Laboratorios Silanes, we aim to solidify Hanmi Pharmaceutical's presence in the Latin American market and leverage this as a foundation to further strengthen our competitiveness in the global pharmaceutical industry."

Official Websites: www.hanmipharm.com

About Hanmi Pharmaceutical:

Hanmi Pharmaceutical is an R&D-focused pharmaceutical company committed to developing globally innovative therapies in areas of high unmet medical needs such as obesity/metabolism, oncology, and rare diseases. Hanmi leverages proprietary platform technologies, including long-acting biologics and bispecific antibodies, to address unmet medical needs. The company emphasizes open innovation and has established numerous global partnerships to advance its research and development efforts.

View original content to download multimedia:https://www.prnewswire.com/news-releases/hanmi-pharmaceuticals-gugutams-to-be-launched-in-mexico-as-aditams-marking-the-start-of-full-scale-latin-america-expansion-302417867.html

SOURCE Hanmi Pharmaceutical